Aktis Oncology, Inc. AKTS
Aktis Oncology, Inc. (Nasdaq: AKTS) is an oncology drug developer. Its lead program, [225Ac]Ac-AKY-1189, is in Phase 1 for Locally advanced or metastatic urothelial cancer (Nectin-4 expressing solid tumors). Its next catalyst on record is [225Ac]Ac-AKY-1189: Preliminary results from Part-1 dose escalation portion of Phase 1b trial (Q1 2027).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: [225Ac]Ac-AKY-1189 — Preliminary results from Part-1 dose escalation portion of Phase 1b trial (Q1 2027). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| [225Ac]Ac-AKY-1189 | Nectin-4 expressing tumors, urothelial cancer | radiopharmaceutical | Phase 1 |
| [225Ac]Ac-AKY-2519 | B7-H3 expressing tumors | radiopharmaceutical | Pre-clinical |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 1 oncology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.